Soft Tissue Augmentation Around Dental Implants Using Connective Tissue Graft, Submerged Tenting Abutment, or Sub-crestal Implant Placement

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age20+
SponsorMisr International University

About this trial

Peri-implant soft tissue thickness is an important determinant of the long-term stability and success of dental implants. Patients with a thin peri-implant soft tissue phenotype are at increased risk of soft tissue recession, marginal bone loss, and compromised esthetic and functional outcomes. Subepithelial connective tissue graft (SCTG) is considered the gold standard for soft tissue augmentation; however, it requires harvesting tissue from the palate, increasing surgical complexity, operative time, and postoperative morbidity. Less invasive approaches, including submerged tenting abutments and subcrestal implant placement, have been proposed as alternatives to improve peri-implant soft tissue dimensions while reducing patient morbidity, but direct comparative clinical evidence remains limited.

This investigator-initiated, single-center, randomized, parallel-group clinical trial will compare three approaches for peri-implant soft tissue augmentation in patients with a thin peri-implant soft tissue phenotype requiring a single dental implant in the posterior mandible. Eligible implant sites will be randomly assigned in a 1:1:1 allocation ratio to receive either subepithelial connective tissue grafting, submerged tenting abutment placement, or subcrestal implant placement during implant surgery.

The primary objective is to compare changes in peri-implant soft tissue thickness using three-dimensional digital intraoral scanning over a 12-month follow-up period. Secondary objectives include evaluation of keratinized tissue width, clinical soft tissue thickness, histological characteristics of peri-implant soft tissue, peri-implant crestal bone level changes, postoperative pain, operative time, patient-reported satisfaction, and postoperative complications. The results of this study are expected to provide evidence regarding whether minimally invasive treatment approaches can achieve clinical outcomes comparable to connective tissue grafting while reducing surgical morbidity and improving patient-centered outcomes.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adults aged 20 years or older.

Partially edentulous patients requiring a single dental implant in the posterior mandible.

Thin peri-implant soft tissue phenotype (<2 mm).

Horizontal alveolar ridge width of at least 6 mm.

Disqualifiers

Local pathological lesions affecting the surgical site.

Smoking.

Pregnancy or breastfeeding.

Alcohol abuse or parafunctional habits that may compromise implant survival or wound healing.

Trial design

Design model

Parallel

Treatments tested in this trial

  • subepithelial connective tissue graft

    Procedure/Surgery

    Harvesting of an autogenous connective tissue graft from the palate and placement over an equicrestally positioned dental implant to augment peri-implant soft tissue thickness.

  • Submerged Tenting Abutment

    Device

    Placement of a submerged low-profile tenting healing abutment over an equicrestally positioned dental implant to support peri-implant soft tissue during healing.

  • Sub-crestal Implant Placement

    Procedure/Surgery

    Placement of a dental implant approximately 2 mm apical to the alveolar crest without soft tissue grafting or tenting abutment placement.

Treatment groups

30 Participants
are divided into 3 treatment groups
Group A: Subepithelial Connective Tissue Graft (SCTG)Experimental treatment 1 intervention
Group B: Submerged Tenting AbutmentExperimental treatment 1 intervention
Group C: Subcrestal Implant PlacementExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Change in Peri-implant Soft Tissue Thickness

Change in peri-implant soft tissue thickness from baseline measured using three-dimensional digital intraoral scanning (Medit Intraoral Scanner) and digital volumetric analysis (Medit Design software). Measurements will be performed by blinded outcome assessors and expressed in millimeters (mm).

Time frame
Baseline, 3 months, 6 months, and 12 months after implant placement.

Secondary outcomes

1

Histological Characteristics of Peri-implant Soft Tissue

Histological evaluation of peri-implant soft tissue biopsy specimens obtained during second-stage implant surgery. Tissue sections will be stained with hematoxylin and eosin and Masson's trichrome to assess epithelial thickness and collagen density.

Time frame
3 months
2

Clinical Peri-implant Soft Tissue Thickness

Clinical measurement of peri-implant soft tissue thickness using standardized transgingival probing.

Time frame
Baseline, 3 months, 6 months, and 12 months
3

Postoperative Pain

Participant-reported postoperative pain measured using a 10-point Visual Analog Scale (VAS). The scale ranges from 0 to 10, where 0 = no pain, 1-3 = mild pain, 4-6 = moderate pain, 7-9 = severe pain, and 10 = worst pain imaginable (very severe pain). Higher scores indicate greater postoperative pain.

Time frame
Daily during the first 10 postoperative days
4

Peri-implant Crestal Bone Level Changes

Changes in peri-implant crestal bone level assessed using standardized periapical radiographs analyzed with ImageJ software.

Time frame
Baseline, 3 months, 6 months, and 12 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.